BDX
vs
S
S&P/ASX 300
BDX
Over the past 12 months, BDX has outperformed S&P/ASX 300, delivering a return of +11% compared to the S&P/ASX 300's +7% growth.
Stocks Performance
BDX vs S&P/ASX 300
Performance Gap
BDX vs S&P/ASX 300
Performance By Year
BDX vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
BCAL Diagnostics Ltd
Glance View
BCAL Diagnostics Ltd. develops screening tests for the early detection of breast cancer. The company is headquartered in Sydney, New South Wales. The company went IPO on 2021-07-21. The firm is developing a blood screening test to improve the early diagnosis and monitoring of breast cancer that is safe, accurate and available to all women regardless of age, race and geographic location. The company has developed a non-invasive blood test for the detection of breast cancer. The firm is developing an in vitro diagnostic test (IVD) that confirms a fingerprint of lipid biomarkers extracted from extracellular vehicles (EVs) from a patient's plasma or blood sample to diagnose the presence of cancer cells in a patient’s body. BCAL has partnered with integrated cancer care and cardiac provider GenesisCare to conduct clinical research required for regulatory approvals across jurisdictions.